Merck's KEYTRUDA Plus Enfortumab Vedotin Approved In Canada For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab for injection), Merck's anti-PD-1 therapy, in combination with enfortumab vedotin, an antibody-drug
Merck got permission in Canada to sell a new cancer medicine combination for patients who can't use a standard treatment. This shows the drug works and could help Merck sell more medicine and grow its business.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.